insights_auto
Prečo akcie GIFLF klesli 5,24%?
Preskúmať podrobnejšiechevron_right
GIFLF:OTCMKTS
Grifols SA Class A
10,55 USD
arrow_downward
-5,24%(-0,58) 1 d.
13. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GIFLF…
Otvoriť
10,55 USD
Vysoká
10,55 USD
Nízka
10,55 USD
Trh. kap.
6,65 mld.
Priem. obj.
543,00
Objem
9,70 tis.
Max. za 52 týž.
12,90 USD
Min. za 52 týž.
10,13 USD
Beta
0,90
Akcie v obehu
426,13 mil.
Počet zamestnancov
25 tis.
Otvoriť
10,55 USD
Vysoká
10,55 USD
Nízka
10,55 USD
Trh. kap.
6,65 mld.
Priem. obj.
543,00
Objem
9,70 tis.
Max. za 52 týž.
12,90 USD
Min. za 52 týž.
10,13 USD
Beta
0,90
Akcie v obehu
426,13 mil.
Počet zamestnancov
25 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
MarketBeat
·
pred 3 hodinami
Grifols, S.A. (NASDAQ:GRFS) Shares Shorted: Short Interest Up 105.0% in September
ad-hoc-news.de
·
pred 1 dňom
Wall Street Zen downgrades Grifols stock from Buy to Hold
Profil
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Informácie o subjekte Grifols SA Class A
Generálny riaditeľNacho Abia
Zamestnanci25 tis.
Dátum založenia18. 11. 1940
Hlavné sídlo-
Odvetvie-
Webgrifols.com